Eisai and Ono Pharmaceutical are planning to conduct a Phase Ib clinical trial of Lenvima (lenvatinib mesylate) in combination with Opdivo (nivolumab), as part of their collaboration agreement to jointly develop the therapy for hepatocellular carcinoma (HCC).

Eisai’s lenvatinib is an oral inhibitor of multiple receptor tyrosine kinase (RTK), kinase activities of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) receptors.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Introduced in Japan by Ono in 2014, Opdivo is a PD-1 immune checkpoint inhibitor that utilises the body’s immune system to help restore anti-tumour immune response.

Planned to be conducted in Japan, the Phase Ib trial will evaluate the safety, tolerability and efficacy of the combination therapy.

Eisai oncology business group vice-president and chief medicine creation officer Dr Takashi Owa said: “Our non-clinical research has demonstrated synergistic anti-tumour activities in the Lenvima and anti-PD1 antibody combination, which are considered to be a result of an immunostimulatory response through a reduction in immunosuppressive tumour-associated macrophages and an increase in cytotoxic T-lymphocytes by Lenvima.”

"As we believe that the combination therapy may exert more excellent therapeutic efficacy compared to the monotherapy, we are very pleased to pursue the potential for developing the combination therapy of Opdivo with lenvatinib."

The firm is additionally conducting a Phase III trial of lenvatinib in separate combinations with everolimus and pembrolizumab for renal cell carcinoma and a Phase Ib/II trial in combination with pembrolizumab to treat select solid tumours.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Ono Clinical Development vice-president executive director Hiroshi Awata said: "We have been actively engaged in the development of Opdivo not only in monotherapy, but combination therapies with other agents.

“As we believe that the combination therapy may exert more excellent therapeutic efficacy compared to the monotherapy, we are very pleased to pursue the potential for developing the combination therapy of Opdivo with lenvatinib.”

Opdivo is being further investigated by the firm in a Phase III clinical trial in Japan for treating HCC.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact